Deyan Wu

Prof. Dr. Deyan Wu

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2023 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
HLHuan Liu
Huan Liu
ZYZiqing Yao
Ziqing Yao
MSMingna Sun
Mingna Sun
CZChao Zhang
Chao Zhang
YHYi-You Huang
Yi-You Huang
XZXuehua Zheng
Xuehua Zheng

18 May 2024 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SWSen Wang
Sen Wang
GYGuofeng Yang
Guofeng Yang
KZKai Zhang
Kai Zhang
ZCZhexin Chen
Zhexin Chen
MQMeiying Qiu
Meiying Qiu
DWDeyan Wu
Deyan Wu

23 April 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JCJinhui Cai
Jinhui Cai
XWXue Wang
Xue Wang
FZFeng Zhang
Feng Zhang
TZTianshen Zheng
Tianshen Zheng
ZCZhuo Chen
Zhuo Chen
DWDeyan Wu
Deyan Wu
Background/Objectives: PDE4 is a key regulator of cAMP signaling and a clinically validated anti-inflammatory target; however, the use of PDE4 inhibitors is often limited by adverse effects such as nausea, vomiting, and diarrhea. The natural compound braylin was previously identified as a novel PDE4 inhibitor scaffold, exhibiting an IC50 of 0.96 µM. Using the PDE4–braylin co-crystal structure, we conducted structure-based design and optimization to enhance its potency. Methods: A series of novel braylin derivatives was synthesized and characterized. Their inhibitory activities against PDE4D were evaluated via enzymatic assays, and binding thermodynamics were analyzed by isothermal titration calorimetry (ITC). Molecular modeling was used to predict binding modes, and anti-inflammatory effects were assessed in LPS-stimulated macrophages. Results: Structure-guided optimization yielded lead compound L27, which showed significantly improved PDE4D inhibition (IC50 = 67 nM) and high-affinity binding (Kd = 45 nM) as confirmed by ITC. L27 also exhibited remarkable selectivity against PDE isoforms. Molecular simulations highlighted key interactions with Gln369 and hydrophobic residues in the PDE4 active site. In cellular assays, L27 dose-dependently suppressed LPS-induced inflammation in macrophages at non-cytotoxic concentrations with efficacy comparable to roflumilast. Conclusions: We developed L27, a potent and selective PDE4 inhibitor derived from natural braylin. It demonstrated promising in vitro anti-inflammatory activity and represents a valuable lead for further therapeutic development.

30 August 2024 in Research Square
Verified
Preprint
Open access
PDF file
ZWZongmin Wu
Zongmin Wu
FZFurong Zhang
Furong Zhang
ZCZhexin Chen
Zhexin Chen
XWXue Wang
Xue Wang
XLXingfu Liu
Xingfu Liu
DWDeyan Wu
Deyan Wu
Phosphodiesterases (PDEs) are important intracellular enzymes that hydrolyze the second messengers cAMP and/or cGMP. Now several studies have shown that PDE4 received particular attention due to it represents the most prominent cAMP-metabolising enzyme involved in many diseases. In this study, the hit compound (PTC-209) with moderate PDE4 inhibitory activity (IC50 of 4.8±0.2 μM) was discovered by screening of our internal compound library. And a series of 4-(imidazo[1,2-a]pyrimidin-3-yl)thiazol-2-amine derivatives as novel PDE4 inhibitors starting from PTC-209 were successfully designed and synthesized using a structure-based discovery strategy. L19, the most potent inhibitor, exhibited good inhibitory activity (IC50 of 0.51±0.02 μM) and remarkable metabolic stability in rat liver microsomes. The results emphasized the successful application of screening and discovery of new scaffolds that can be helpful for optimization of novel PDE4 inhibitors.

23 September 2024 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
ZWZongmin Wu
Zongmin Wu
FZFurong Zhang
Furong Zhang
ZCZhexin Chen
Zhexin Chen
XWXue Wang
Xue Wang
XLXingfu Liu
Xingfu Liu
DWDeyan Wu
Deyan Wu